Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis
- PMID: 20585879
- DOI: 10.1245/s10434-010-1154-5
Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis
Abstract
Background: Management of neuroendocrine tumor liver metastasis (NELM) remains controversial, with some advocating an aggressive surgical approach while others have adopted a more conservative strategy. We sought to define the efficacy of the surgical management of NELM in a large multicenter international cohort of patients.
Methods: We identified 339 patients who underwent surgical management for NELM from 1985 to 2009 from an international database of eight major hepatobiliary centers. Relevant clinicopathologic data were assessed using Kaplan-Meier and Cox regression models.
Results: Most patients had a pancreatic (40%) or small bowel (25%) neuroendocrine tumor (NET) primary. The majority of patients (60%) had bilateral liver disease. At surgery, 78% of patients underwent hepatic resection, 3% ablation alone, and 19% resection + ablation. Major hepatectomy was performed in 45% of patients, and 14% underwent a second liver operation. Carcinoid was the most common NET histological subtype (53%). Median survival was 125 months, with overall 5- and 10-year survival of 74%, and 51%, respectively. Disease recurred in 94% of patients at 5 years. Patients with hormonally functional NET who had R0/R1 resection benefited the most from surgery (P = 0.01). On multivariate analyses, synchronous disease [hazard ratio (HR) = 1.9], nonfunctional NET hormonal status (HR = 2.0), and extrahepatic disease (HR = 3.0) remained predictive of worse survival (all P < 0.05).
Conclusions: Liver-directed surgery for NELM is associated with prolonged survival; however, the majority of patients will develop recurrent disease. Patients with hormonally functional hepatic metastasis without prior extrahepatic or synchronous disease derive the greatest survival benefit from surgical management.
Similar articles
-
Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.Ann Surg Oncol. 2011 Dec;18(13):3657-65. doi: 10.1245/s10434-011-1832-y. Epub 2011 Jun 17. Ann Surg Oncol. 2011. PMID: 21681380
-
Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach.Surgery. 2011 Feb;149(2):209-20. doi: 10.1016/j.surg.2010.06.008. Epub 2010 Aug 2. Surgery. 2011. PMID: 20674950
-
Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.Ann Surg Oncol. 2015 Mar;22(3):1000-7. doi: 10.1245/s10434-014-4016-8. Epub 2014 Sep 5. Ann Surg Oncol. 2015. PMID: 25190116
-
[Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies].Zentralbl Chir. 2009 Sep;134(5):410-7. doi: 10.1055/s-0029-1224607. Epub 2009 Sep 15. Zentralbl Chir. 2009. PMID: 19757340 Review. German.
-
The surgical management of neuroendocrine tumour hepatic metastases.Eur J Surg Oncol. 2013 Mar;39(3):224-8. doi: 10.1016/j.ejso.2012.12.001. Epub 2013 Jan 3. Eur J Surg Oncol. 2013. PMID: 23290582 Review.
Cited by
-
Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Curr Oncol. 2024 Apr 5;31(4):2076-2091. doi: 10.3390/curroncol31040154. Curr Oncol. 2024. PMID: 38668057 Free PMC article. Review.
-
Hepatopancreaticobiliary Resection Arginine Immunomodulation (PRIMe) trial: protocol for a randomised phase II trial of the impact of perioperative immunomodulation on immune function following resection for hepatopancreaticobiliary malignancy.BMJ Open. 2024 Apr 5;14(4):e072159. doi: 10.1136/bmjopen-2023-072159. BMJ Open. 2024. PMID: 38580363 Free PMC article.
-
[Current views on the treatment of insulinoma].Probl Endokrinol (Mosk). 2024 Feb 28;70(1):46-55. doi: 10.14341/probl13281. Probl Endokrinol (Mosk). 2024. PMID: 38433541 Free PMC article. Review. Russian.
-
H-Dot Mediated Nanotherapeutics Mitigate Systemic Toxicity of Platinum-Based Anticancer Drugs.Int J Mol Sci. 2023 Oct 23;24(20):15466. doi: 10.3390/ijms242015466. Int J Mol Sci. 2023. PMID: 37895146 Free PMC article.
-
The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors.Curr Treat Options Oncol. 2023 Nov;24(11):1651-1665. doi: 10.1007/s11864-023-01124-w. Epub 2023 Oct 26. Curr Treat Options Oncol. 2023. PMID: 37882889 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical